Cincinnati, Ohio
Cancer clinical trials in Cincinnati, OH
154 cancer studies are recruiting participants at sites in Cincinnati as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Cincinnati at a glance
- 154 studies are recruiting at a site in Cincinnati.
- By phase: Early Phase 1 (1), Phase 1 (15), Phase 1/2 (22), Phase 2 (30), Phase 2/3 (3), Phase 3 (57), Phase 4 (2), No phase (4), Observational (20). Studies of devices and behavioral approaches have no phase.
- By sponsor: industry (88), university, hospital or other (56), government (10).
- By research area: Lymphoma (48), Lung Cancer (41), Breast Cancer (27), Prostate Cancer (19), Pancreatic Cancer (11), Melanoma (8).
- Most recent update to one of these records: November 16, 2026.
Breast cancer studies recruiting in Cincinnati
Basic details from each study's public record (the 30 most recently updated of 154). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study sites
- The Christ Hospital · University of Cincinnati Cancer Center-UC Medical Center
- Registry record
- NCT03418961 · updated
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Phase 2
- All ages
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Good Samaritan Hospital - Cincinnati
- Registry record
- NCT05564377 · updated
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Good Samaritan Hospital-TriHealth Cancer institute ( Site 0027)
- Registry record
- NCT06966700 · updated
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
- No phase
- Ages 18 and older
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study sites
- Bethesda North Hospital · Good Samaritan Hospital - Cincinnati · Oncology Hematology Care Inc-Kenwood
- Registry record
- NCT03723928 · updated
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Observational
- Ages 40 to 75
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study sites
- Bethesda North Hospital · Good Samaritan Hospital - Cincinnati · Oncology Hematology Care Inc-Kenwood
- Registry record
- NCT05334069 · updated
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Gilead Sciences
- Study sites
- Good Samaritan Hospital · Oncology Hematology Care, Inc.
- Registry record
- NCT05633654 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Cincinnati, OH on ClinicalTrials.gov.
Lung cancer studies recruiting in Cincinnati
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- University of Cincinnati Cancer Center-UC Medical Center
- Registry record
- NCT06287775 · updated
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0103)
- Registry record
- NCT06345729 · updated
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- Oncology Hematology Care
- Registry record
- NCT06646276 · updated
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
- Phase 2
- Ages 1 to 18
- All sexes
- Sponsor
- Novartis Pharmaceuticals
- Study site
- Cinn Children Hosp Medical Center
- Registry record
- NCT07354074 · updated
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- University of Cincinnati Medical Center
- Registry record
- NCT06561386 · updated
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- University of Cincinnati Medical Center ( Site 0119)
- Registry record
- NCT06623422 · updated
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Pfizer
- Study site
- Oncology_Hematology Care Clinical Trials,LLC
- Registry record
- NCT07144280 · updated
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- The Christ Hospital
- Registry record
- NCT07361497 · updated
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- TRIANA Biomedicines, Inc.
- Study site
- University of Cincinnati Cancer Center
- Registry record
- NCT07491497 · updated
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- University of Cincinnati Cancer Center-UC Medical Center
- Registry record
- NCT04181060 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Cincinnati, OH on ClinicalTrials.gov.
Prostate cancer studies recruiting in Cincinnati
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Study sites
- Bethesda North Hospital · Good Samaritan Hospital - Cincinnati
- Registry record
- NCT04423211 · updated
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
- Phase 1
- Ages 18 and older
- Male participants
- Sponsor
- Amgen
- Study site
- Oncology Hematology Care Incorporated
- Registry record
- NCT04221542 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Cincinnati, OH on ClinicalTrials.gov.
Melanoma studies recruiting in Cincinnati
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
- Phase 3
- Ages 75 and older
- All sexes
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Study sites
- Bethesda North Hospital · Good Samaritan Hospital - Cincinnati · TriHealth Cancer Institute-Anderson
- Registry record
- NCT07068074 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Cincinnati, OH on ClinicalTrials.gov.
Lymphoma studies recruiting in Cincinnati
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Nurix Therapeutics, Inc.
- Study site
- University of Cincinnati
- Registry record
- NCT07221500 · updated
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
- Phase 1
- Ages 0 to 18
- All sexes
- Sponsor
- Autolus Limited
- Study site
- Cincinnati Children's Hospital
- Registry record
- NCT06173518 · updated
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Oncology_Hematology Care Clinical Trials, LLC (OHC) ( Site 8002)
- Registry record
- NCT06717347 · updated
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- University of Cincinnati Medical Center ( Site 0156)
- Registry record
- NCT06890884 · updated
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- University of Cincinnati Cancer Center-UC Medical Center
- Registry record
- NCT03739814 · updated
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- Ages 1 to 30
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Cincinnati Children's Hospital Medical Center
- Registry record
- NCT04546399 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Cincinnati Children's Hospital Medical Center
- Registry record
- NCT05675410 · updated
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
- Phase 3
- Ages 1 and older
- All sexes
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Study site
- Cincinnati Children's Hospital Medical Center
- Registry record
- NCT07223021 · updated
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- University of Cincinnati Cancer Center-UC Medical Center
- Registry record
- NCT06649812 · updated
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
- Phase 1/2
- From 6 months, up to 30 years
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- Cincinnati Children's Hospital Medical Center
- Registry record
- NCT05533775 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Cincinnati, OH on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Cincinnati
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Immuneering Corporation
- Study site
- University of Cincinnati Cancer Center
- Registry record
- NCT07562152 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Cincinnati, OH on ClinicalTrials.gov.
Ask about studies near Cincinnati
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in Ohio
All Ohio locations
542 studies recruiting across 70 cities.
Columbus
269 studies recruiting.
Cleveland
205 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections